Patent application number | Description | Published |
20090274238 | MODULATING APPARATUS, MOBILE COMMUNICATION SYSTEM, MODULATING METHOD, AND COMMUNICATION METHOD - An encoder encodes sound data and the like to generate a binary signal. A mapper converts the binary signal into a quaternary symbol and outputs the quaternary symbol. A base band filter includes a root raised cosine filter and a sinc filter. The base band filter blocks a predetermined frequency component of a symbol to shape the symbol into a waveform signal and outputs the waveform signal shaped. An FM modulator transmits a signal subjected to FM modulation according to a magnitude of an amplitude of a waveform signal to a receiving unit. When a symbol of ±3 is outputted from the mapper, a frequency shift of a signal transmitted from the FM modulator has a predetermined value in a range of ±0.822 [kHz] to ±0.952 [kHz]. This makes it possible to provide a modulating apparatus, a mobile communication system, a modulating method, and a communication method that use a modulating method that can conform to the FCC rule to be enforced in 2005 without using a linear power amplifier. | 11-05-2009 |
20100056081 | MODULATING APPARATUS, MOBILE COMMUNICATION SYSTEM, MODULATING METHOD, AND COMMUNICATION METHOD - An encoder encodes audio data and the like to generate a binary signal. A mapper converts the binary signal into a four-level symbol and outputs the four-level symbol. A base band filter includes a root raised cosine filter and a sinc filter. The base band filter blocks a predetermined frequency component of a symbol to shape the symbol into a waveform signal and outputs the waveform signal shape. An FM modulator transmits a signal subjected to FM modulation according to a magnitude of an amplitude of a waveform signal to a receiving unit. When a symbol of ±3 is outputted from the mapper, a frequency shift of a signal transmitted from the FM modulator has a predetermined value in a range of ±0.822 [kHz] to ±0.952 [kHz]. This makes it possible to provide a modulating apparatus, a mobile communication system, a modulating method, and a communication method that use a modulating method that can conform to the FCC rule to be enforced in 2005 without using a linear power amplifier. | 03-04-2010 |
20100062990 | NOVEL PSEUDOGLYCOLIPID AND USE THEREOF - The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, | 03-11-2010 |
20100129339 | NKT CELL-STIMULATING AGENT FOR ADMINISTRATION THROUGH UPPER RESPIRATORY TRACT MUCOUS MEMBRANE - The present invention provides an NKT cell stimulating agent containing antigen-presenting cells pulsed with an NKT cell ligand, to be administered submucosally in the upper airway. By submucosal administration in the upper airway, it is possible to stimulate NKT cells and stimulate immune reactions extremely efficiently with a small number of NKT cell ligand-pulsed antigen-presenting cells. By submucosal administration in the upper airway, NKT cells can be induced selectively in cervical lymph nodes. | 05-27-2010 |
20110020932 | IN VITRO DIFFERENTIATION/INDUCTION OF LYMPHOCYTE FROM STEM CELL HAVING GENOTYPE PROVIDED AFTER GENE RECONSTITUTION - The present invention provides a production method of a functional differentiated cell having a post-rearrangement genotype of a particular antigen receptor gene, which includes culturing a stem cell having the genotype in a medium to give the differentiated cell derived from the stem cell. As the stem cell having the genotype, a stem cell (e.g., ES cell) established by transplantation of the nucleus of a cell having the genotype is preferable. As the differentiated cell, NKT cell is preferable. | 01-27-2011 |
20110052598 | METHOD FOR SCREENING OF THERAPEUTIC AGENT FOR ALLERGIC AIRWAY INFLAMMATION AND/OR AIRWAY HYPERSENSITIVITY USING IL-17RB-POSITIVE NKT CELL - The invention provides a method of screening a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, comprising using an IL-17RB positive NKT cell, as well as a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, containing a substance capable of inhibiting or eliminating the Th2 cell-like function of an IL-17RB positive NKT cell as an active ingredient. | 03-03-2011 |
20110104188 | NOVEL GLYCOLIPID AND USE THEREOF - The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like. The glycolipid is represented by the formula (1) or a salt thereof | 05-05-2011 |
20110231944 | B CELL-DERIVED IPS CELLS AND APPLICATION THEREOF - Provided are a B cell-derived iPS cell generated using a convenient technique, a technology for providing a human antibody at low cost using the iPS cell, an immunologically humanized mouse prepared using cells differentiated from the iPS cell, and the like. Also provided are a cloned cell obtained by contacting a B cell with nuclear reprogramming factors excluding C/EBPα and Pax5 expression inhibiting substances, particularly nucleic acids that encode Oct3/4, Sox2, Klf4 and c-Myc, wherein the cloned cell has an immunoglobulin gene rearranged therein and possesses pluripotency and replication competence (B-iPS cell). Still also provided are a method of producing a monoclonal antibody against a specified antigen, comprising recovering an antibody from a culture of B cells obtained by differentiating a B-iPS cell derived from a B cell immunized with the specified antigen, and a method of generating an immunologically humanized mouse, comprising transplanting to an immunodeficient mouse a human immunohematological system cell obtained by differentiating a B-iPS cell. | 09-22-2011 |
20130209485 | THERAPEUTIC AGENT OF NON-ALLERGIC AIRWAY INFLAMMATION AND/OR NON-ALLERGIC HYPERRESPONSIVE AIRWAY - The invention provides a therapeutic agent for non-allergic airway inflammation and/or non-allergic airway hyperreactivity, containing a substance capable of inhibiting or eliminating the Th17 cell-like function of an IL-17RB positive NKT cells as an active ingredient; a prophylactic or therapeutic method for non-allergic airway inflammation and/or non-allergic airway hyperreactivity, using the substance, and a method of screening for a therapeutic agent for non-allergic airway inflammation and/or non-allergic airway hyperreactivity, containing a step of measuring a Th17 cell-like function of IL-17RB positive NKT cells. | 08-15-2013 |
20150071991 | DRUG HAVING REGULATORY CELL LIGAND CONTAINED IN LIPOSOME - A liposome containing a regulatory cell ligand such as α-galactosyl ceramide or β-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc. | 03-12-2015 |
Patent application number | Description | Published |
20090214596 | Nasal Vaccine - The present invention provides a nasal vaccine capable of intranasally inducing an effective immunity reaction. Specifically, the invention provides a nasal vaccine containing a compound having an NKT cell-activating action, particularly a compound represented by the formula (I): | 08-27-2009 |
20090215707 | COMPOUND HAVING CYCLIC STRUCTURE AND USE THEREOF - The present invention relates to a compound represented by the following formula (1′) | 08-27-2009 |
20090221516 | NOVEL GLYCOLIPID AND USE THEREOF - The present invention provide a compound represented by the following formula (1) | 09-03-2009 |
20100083393 | METHOD OF CONSTRUCTING CLONE MAMMAL - The present invention provides a method of producing a cloned mammal, which uses a mammalian natural killer T cell as a donor cell, a cloned mammal obtained by the method, a method of obtaining an ES cell from the embryo of the cloned animal and an ES cell obtained by the method. | 04-01-2010 |
20110142813 | Use Of Anti-Cancer Cell Composition For Treatment Of Head And Neck Cancer, Which Is Intended To Be Administered To Nutrient Artery Of Tumor - To provide a method of efficiently delivering cells having an anti-tumor activity to tumor tissues to evoke a stronger anti-tumor reaction, and a method of providing a more effective tumor regression effect, both in a cellular immunotherapy for cancer utilizing cells having an anti-tumor activity or antigen presenting cells for activating cells capable of exhibiting an anti-tumor activity. Provided are: a method of treating head and neck cancer, comprising administering an anti-cancer cell composition containing NKT cells activated in vitro with an NKT cell ligand into the tumor-feeding artery, and administering an NKT cell-stimulating agent containing antigen presenting cells treated with an NKT cell ligand through the upper respiratory tract mucous membrane; a use, in anti-cancer treatment of head and neck region, of the anti-cancer cell composition and the NKT cell-stimulating agent; a kit comprising the anti-cancer cell composition and the NKT cell-stimulating agent; and the anti-cancer cell composition. | 06-16-2011 |
20110224158 | ESTERIFIED ALPHA-GALACTOSYLCERAMIDE - The invention provides esterified α-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): | 09-15-2011 |
20110236362 | NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM - Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell. Also provided are an iPS cell having TCRα rearranged to NKT-TCR (NKT-iPS cell), obtained by contacting a somatic cell, such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, with nuclear reprogramming factors, isolated NKT cells obtained by differentiating the iPS cell ex vivo (iPS-NKT cell), a method of generating CD4/CD8-double positive NKT cells (DP-NKT cells) and mature NKT cells from NKT-iPS cells by altering the combination of feeder cells and/or cytokines, a method of expanding the iPS-NKT cells, and an NKT cell cytotherapy agent comprising NKT cells activated with α-galactosyl ceramide (α-GalCer), or iPS-NKT cells, and α-GalCer in combination. | 09-29-2011 |
20130005669 | NOVEL SYNTHETIC GLYCOLIPID AND USE THEREOF - A compound represented by the following formula (1): | 01-03-2013 |
20130295142 | IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH ALPHA CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM V-ALPHA-J-ALPHA, AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS - The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the α-chain region of the T cell receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the α-chain region of a T cell receptor (TCR) gene has been rearranged to uniform Vα-Jα. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease. | 11-07-2013 |